Immune Function and the Progression to T1D

Part of paid clinical trials in Gainesville, Florida.

Sponsor
University of Florida
Study ID
NCT05899439
Status
Recruiting

Conditions

Eligibility Criteria

Sex
ALL
Age
0 Years - 100 Years
Healthy Volunteers
Accepted

Interventions

  • blood draw — OTHER
    a peripheral blood draw

Study Details

To elucidate the mechanisms by which type 1 diabetes-associated genes; IFIH1, TYK2, IKZF4, as well as total genetic risk, impart functional immunoregulatory abnormalities that result in expansion of self-reactive adaptive immune cells, defective regulatory/effector mechanisms in T cells, inflammatory antigen presenting cells, and abnormal immune function in T cells and B cells.

Key Dates

First listed
Jun 12, 2023
Start date
Jan 1, 2005
Status verified
Apr 2026
Primary completion
Jan 1, 2085
Completion
Jan 1, 2085

Study Design

Enrollment
2,800 participants (estimated)

Arms

  • Arm: Subjects with diabetes age 0 to 100 years
    People who have not been diagnosed with type 1 diabetes
  • Arm: Subjects with type 1 diabetes age 0 to 100 years
    People who have been diagnosed with type 1 diabetes

Primary Outcome Measure

the number of participants who become at risk for development of type 1 diabetes [ Time Frame: through study completion, up to 25 years ]

Central Contacts

Locations (3)

FacilityCityStateZIPSite coordinators
Kieran McGrailGainesvilleFlorida32610
Kieran McGrail
352-273-9299
Todd Brusko, PhD (PRINCIPAL_INVESTIGATOR)
The Ohio State UniversityColumbusOhio43210
Billur Akkaya, MD DPhil
614-688-1187
Baylor College of Medicine, Center for Research Advancement - Texas Children's HospitalHoustonTexas77030
Maria Redondo, MD, PhD, MPH
832-822-1019
Franca Erhiawarie
832-824-3372

Find similar trials in Gainesville, FL

By condition
By specialty

Related Studies